首页> 外文会议>International Congress on Coronary Artery Disease. >Aortic Valve Replacement or Heart Transplantation in Patients with Aortic Stenosis and Severe Left Ventricular Dysfunction
【24h】

Aortic Valve Replacement or Heart Transplantation in Patients with Aortic Stenosis and Severe Left Ventricular Dysfunction

机译:主动脉狭窄和严重左心室功能障碍患者的主动脉瓣替代或心脏移植

获取原文

摘要

Introduction: Decisions to perform aortic valve replacement (AVR) or heart transplantation (HTx) for aortic stenosis (AS) with severe left ventricular dysfunction is difficult and may be affected by prior myocardial infarction (MI) and coronary artery disease (CAD). Methods: Patients who underwent AVR from 1988 to 2001 with left ventricular ejection fraction (LVEF) < 30% and severe AS (aortic valve area [AVA] <1.0cm2; n=51) were assessed for operative mortality, late survival, and predictors of outcome, and compared with HTx. Subsequently, 131 patients with LVEF < 35% who underwent AVR for critical AS (AVA <0.8cm2) were evaluated. Results: In the first 51 patients, 3-year survival was 100% with no CAD, and 45%±10% with CAD (P<.05); 3-year survival was 88%±12% with no bypass, 73%±12% with one or two grafts, and 18%±11% with three grafts (P<.01). Survival with HTx was 78% at 3 years. In the subsequent analysis of 131 patients, 90-day survivors were followed for 4.6±3.5 years. Advanced age (P<.001) was the only predictor of long-term mortality. LVEF improved from 28.5%±5.2% before AVR to 45.4%±13.2% at 1-month postoperatively (P<.0001). New York Heart Association class III/IV decreased from 94.2% pre-AVR to 12.8% at 1 year (P<.0001). Predictors of LVEF recovery were no previous MI (P =.007) and higher AS gradient (P =.03). Conclusions: In severe AS and LVEF < 30% with no CAD or CAD requiring one or two bypass grafts, AVR has survival equal or exceeds HTx. Patients with CAD requiring more than two bypass grafts, survival is significantly reduced, and HTx can be considered.
机译:介绍:对严重左心室功能障碍进行主动脉瓣狭窄(AVR)或心脏移植(HTX)的决定是困难的,并且可能受到先前心肌梗死(MI)和冠状动脉疾病(CAD)的影响。方法:从1988年至2001年接受AVR的患者,左心室喷射分数(LVEF)<30%且严重(主动脉瓣膜区域[AVA] <1.0cm2; n = 51)进行术治疗死亡率,晚期生存和预测因子结果,并与HTX进行比较。随后,评估了131例LVEF <35%的患者,遵循AVR的临界临界(AVA <0.8CM2)。结果:在前51例患者中,3年生存率为100%,没有CAD,45%±10%,CAD(P <.05); 3年生存率为88%±12%,没有旁路,1或两个移植物73%±12%,三个移植物(P <.01),18%±11%。 3年后HTX的存活率为78%。在随后的131名患者的分析中,随访90天的幸存者4.6±3.5岁。高级年龄(P <.001)是长期死亡率的唯一预测因素。在术后1个月之前,平均水平从AVR之前的28.5%±5.2%提高到45.4%±13.2%(P <.0001)。纽约心脏协会III / IV级/ IV级从AVR预先降低至12.8%(P <.0001)。 LVEF恢复的预测因子未以前的MI(p = .007),梯度更高(p = .03)。结论:严重AS和LVEF <30%没有CAD或CAD需要一个或两个旁路移植物,AVR的存活率等于或超过HTX。 CAD患者需要两个以上的旁路移植物,存活率显着降低,并且可以考虑HTX。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号